This research project will work with stroke survivors and their families. In year one, we will design a healthy living programme for stroke survivors and their families. The programme will provide information, education and support. It will help people to learn how to manage their own lifestyle risk factors.
People who have survived a previous stroke or transient ischaemic attack (TIA) are at particularly high risk of subsequent, ‘recurrent’ stroke with 30% having another stroke in the following five years. High blood pressure is the most important reversible risk factor for having a recurrent stroke.
Local stroke survivors have joined in a new stroke research program at the Stroke Association’s Life After Stroke Centre in Bromsgrove on Monday 05 September. STARR (stroke, technology and risk reduction) is a new research program, which will help stroke survivors manage their risk factors for recurrent stroke: a stroke that happens after someone has their first stroke.
Published online (ahead of print in the journal Annals of Neurology), the results of a new study found that one year after arterial ischaemic stroke (AIS), the rate of death, recurrence of stroke, and neurological impairment was lower than reports in previous studies.
On 12 February 2015, at the International Stroke Conference (ISC 2015) in Nashville, USA, the findings of a Stroke Association-funded study were presented, called CADISS (Cervical Artery Dissection In Stroke Study).
This research is focused on assessing the relationship between the variability of the blood flow through the blood vessels supplying the brain, and the risk of stroke in patients who have already had a stroke or “mini-stroke” (TIA) in the past.
The importance of variability in blood pressure after acute stroke
Universty of Oxford News Release:Immediate aspirin after mini-stroke substantially reduces risk of major stroke
The European Stroke Organisation Conference (ESOC) 2018 is currently on from 16-18 May in Gothenburg, Sweden. The first day of ESOC included some truly inspiring scientific sessions, including the WAKE-UP trial, RIGHT-2 trial and CROMIS-2 trials.
This study will investigate whether early initiation of direct anticoagulant drugs will be as safe as later initiation in stroke patients with an abnormal heart rhythm (atrial fibrillation). It will also investigate whether early initiation could lead to fewer recurrent strokes.